Comparison of inducibility of multidrug resistance (MDR)1, multidrug resistance-associated protein (MRP)1, and MRP2 mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 11, 2008, Pages 2068-2072

  Nishimura, Masuhiro ^a   Koeda, Akiko ^b   Morikawa, Hiroshi ^b   Satoh, Tetsuo ^b,c   Narimatsu, Shizuo ^d   Naito, Shinsaku ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b N   (Japan)

^c BUILDING RESEARCH INSTITUTE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cynomolgus monkey; Hepatocyte; Induction; Multidrug resistance 1; Multidrug resistance associated protein 1; Multidrug resistance associated protein 2

Indexed keywords

ABC TRANSPORTER; BETA ACTIN; DEXAMETHASONE; MESSENGER RNA; MICROSOME ENZYME; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OMEPRAZOLE; RIFAMPICIN;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; DRUG ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CULTURE; MALE; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANIMALS; CELLS, CULTURED; CRYOPRESERVATION; DEXAMETHASONE; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MICROSOMES, LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OMEPRAZOLE; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; RNA, MESSENGER; SPECIES SPECIFICITY;

EID: 55549119638     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.2068     Document Type: Article

References (28)

1. Juliano R. L., Ling, V., Biochim. Biophys. Acta, 455, 152-162 (1976).
2. Borst P., Evers R., Kool M., Wijnholds J., J. Natl. Cancer Inst., 92, 1295-1302 (2000).
3. Dean M., Rzhetsky A., Allikmets R., Genome Res., 11, 1156-1166 (2001).
4. Tsuji A., Drug Metab. Pharmacokinet., 17, 253-274 (2002).
5. Eyal S., Lamb J. G., Smith-Yockman M., Yagen B., Fibach E., Altschuler Y., White H. S., Bialer M., Br. J. Pharmacol., 149, 250-260 (2006).
6. Nishimura M., Yamaguchi M., Yamauchi A., Ueda N., Naito S., Drug Metab. Pharmacokinet., 20, 46-54 (2005).
7. Tazuke Y., Kiristioglu I., Heidelberger K. P., Eisenbraun M. D., Teitelbaum D. H., J. Parenter. Enteral Nutr., 28, 1-6 (2004).
8. Han Y., Sugiyama Y., Biol. Pharm. Bull., 29, 1032-1035 (2006).
9. Geick A., Eichelbaum M., Burk O., J. Biol. Chem., 276, 14581-14587 (2001).
10. Mills J. B., Rose K. A., Sadagopan N., Sahi J., de Morais S. M., J. Pharmacol. Exp. Ther., 309, 303-309 (2004).
11. Nishimura M., Yoshitsugu H., Naito S., Hiraoka I., Yakugaku Zasshi, 122, 339-361 (2002).
12. Nishimura M., Koeda A., Suzuki E., Kawano Y., Nakayama M., Satoh T., Narimatsu S., Naito S., Drug Metab. Pharmacokinet., 21, 297-307 (2006).
13. Seglen P. O., Methods Cell Biol., 13, 29-83 (1976).
14. Nishimura M., Koeda A., Suganuma Y., Suzuki E., Shimizu T., Nakayama M., Satoh T., Narimatsu S., Naito S., Drug Metab. Pharmacokinet., 22, 178-186 (2007).
15. Nishimura M., Koeda A., Shimizu T., Nakayama M., Satoh T., Narimatsu S., Naito S., Drug Metab. Pharmacokinet., 23, 45-53 (2008).
16. Nishimura M., Naito S., Biol. Pharm. Bull., 28, 886-892 (2005).
17. Nishimura M., Koeda A., Suzuki E., Shimizu T., Kawano Y., Nakayama M., Satoh T., Narimatsu S., Naito S., Biochem. Biophys. Res. Commun., 346, 1033-1039 (2006).
18. Nishimura M., Naito S., Drug Metab. Pharmacokinet., 20, 452-477 (2005).
19. Nishimura M., Ueda N., Naito S., Biol. Pharm. Bull., 26, 1052-1056 (2003).
20. Morioka Y., Nishimura M., Imai T., Suzuki S., Harada M., Satoh T., Naito S., Drug Metab. Pharmacokinet., 21, 19-28 (2006).
21. Schrenk D., Baus P. R., Ermel N., Klein C., Vorderstemann B., Kauffmann H. M., Toxicol. Lett., 120, 51-57 (2001).
22. Turncliff R. Z., Meier P. J., Brouwer K. L., Drug Metab. Dispos., 32, 834-839 (2004).
23. Kubitz R., Warskulat U., Schmitt M., Häussinger D., Biochem. J., 340, 585-591 (1999).
24. Courtois A., Payen L., Guillouzo A., Fardel O., FEBS Lett., 459, 381-385 (1999).
25. FDA, "Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling," Sep., 2006.
26. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H. P., von Richter O., Zundler J., Kroemer H. K., J. Clin. Invest., 104, 147-153 (1999).
27. Hamman M. A., Bruce M. A., Haehner-Daniels B. D., Hall S. D., Clin. Pharmacol. Ther., 69, 114-121 (2001).
28. Johne A., Brockmöller J., Bauer S., Maurer A., Langheinrich M., Roots I., Clin. Pharmacol. Ther., 66, 338-345 (1999).